News Research news

2026: reflecting on the last year’s research progress and looking at what’s ahead

2025 was one of our most exciting years yet for Parkinson’s research. We saw the launch of EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, the start of recruitment for the phase 3 trial of ambroxol, the forging of new strategic partnerships, and much…


News Press release

Cure Parkinsons and Van Andel Institute renew funding for Parkinson’s clinical trial programme  

Cure Parkinson’s and Van Andel Institute (VAI) have renewed a funding agreement to support the International Linked Clinical Trials (iLCT) programme, the world’s largest drug repurposing clinical trial initiative for Parkinson’s disease.    As part of the three-year agreement, VAI and Cure Parkinson’s each pledge $750,000…


New iLCT Pipeline study: Theracurmin

Cure Parkinson’s is excited to announce the funding of the fourth preclinical project as part of our iLCT Pipeline Research Acceleration Programme. Led by Dr Ayse Ulusoy at the German Center for Neurodegenerative Diseases (DNZE), this preclinical project will evaluate Theracurmin in models of Parkinson’s…


News Research news

An update to our research strategy

Every few years, we set out to review and refresh our research strategy. This document underpins everything we do at Cure Parkinson’s and provides the roadmap for how we plan to move closer to our goal: to identify curative treatments for Parkinson’s, with urgency. As…


News Research news

How a new study on Parkinson’s in the UK gives insights for research

Parkinson’s UK have recently published the results of their nationwide study, which looked at the prevalence of Parkinson’s in the UK. Information from studies like this help us identify gaps in Parkinson’s research and care. We use these insights to help demonstrate the urgent need…